can i get semaglutide from my doctor GLP-1s I would say in this

Dosing Comparison# Survodutide Dosing# Based on Phase 2 trial data and ongoing Phase 3 protocols: Route : Once-weekly subcutaneous injection Dose escalation : Starting dose of 0.25 mg with gradual titration Maintenance doses studied : 2.4 mg, 4.8 mg, and 6.0 mg weekly in Phase 2 Optimal dose : 4.8 mg and 6.0 mg showed greatest efficacy in Phase 2 weight loss trials MASH dosing : Similar dose range evaluated in hepatic endpoints trials Titration rationale : Gradual escalation minimizes GI side effects and allows metabolic adaptation to glucagon receptor activation Tirzepatide Dosing# FDA-approved dosing protocols: Route : Once-weekly subcutaneous injection Starting dose : 2.5 mg weekly for 4 weeks Dose escalation : Increase by 2.5 mg every 4 weeks as tolerated Maintenance doses : 5 mg, 10 mg, or 15 mg weekly Maximum dose : 15 mg weekly Formulation : Prefilled single-dose pens (Mounjaro/Zepbound) and prefilled syringes Storage : Refrigerated

Professional procedures use powerful, FDA-cleared energy to reach the deeper layers of your skin where collagen is produced

A study by Mass Eye and Ear (which was published in JAMA Ophthalmology) found that those on semaglutide were four times more likely to develop NAION (17 of 200 diabetes patients) and seven times more likely to develop NAION if they were also obese or overweight (20 of 361 overweight or obese patients)

For non-diabetic obesity, the cleanest comparison is between two separate trials: STEP 1 (semaglutide 2.4 mg, Wilding et al., NEJM 2021): 14.9% body weight loss at 68 weeks SURMOUNT-1 (tirzepatide 15 mg, Jastreboff et al., NEJM 2022): 20.9% body weight loss at 72 weeks A roughly 6 percentage point gap in average weight loss favors tirzepatide

Patients carrying certain FTO variants, for example, may experience more pronounced inflammatory markers during rapid weight loss, predisposing them to body aches